Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer.

Bauerschlag DO, Schem C, Weigel MT, Von Kaisenberg C, Strauss A, Bauknecht T, Maass N, Meinhold-Heerlein I.

J Cancer Res Clin Oncol. 2010 Jan;136(1):79-88. doi: 10.1007/s00432-009-0639-8.

PMID:
19609560
2.

p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.

Laframboise S, Chapman W, McLaughlin J, Andrulis IL.

Cancer J. 2000 Sep-Oct;6(5):302-8.

PMID:
11079169
3.

Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.

Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schönborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF.

Clin Cancer Res. 2001 Oct;7(10):2984-97.

4.

p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.

Makino T, Yamasaki M, Miyata H, Yoshioka S, Takiguchi S, Fujiwara Y, Nakajima K, Nishida T, Mori M, Doki Y.

Ann Surg Oncol. 2010 Mar;17(3):804-11. doi: 10.1245/s10434-009-0786-9. Epub 2009 Nov 3.

PMID:
19885698
5.

Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer.

Marx D, Meden H, Ziemek T, Lenthe T, Kuhn W, Schauer A.

Eur J Cancer. 1998 May;34(6):845-50.

PMID:
9797696
6.

Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy.

Nakayama K, Kanzaki A, Terada K, Mutoh M, Ogawa K, Sugiyama T, Takenoshita S, Itoh K, Yaegashi N, Miyazaki K, Neamati N, Takebayashi Y.

Clin Cancer Res. 2004 Apr 15;10(8):2804-11.

7.

p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer.

Leonard DG, Travis LB, Addya K, Dores GM, Holowaty EJ, Bergfeldt K, Malkin D, Kohler BA, Lynch CF, Wiklund T, Stovall M, Hall P, Pukkala E, Slater DJ, Felix CA.

Clin Cancer Res. 2002 May;8(5):973-85. Erratum in: Clin Cancer Res. 2002 Aug;8(8):2752-3.

8.

Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.

Levesque MA, Katsaros D, Massobrio M, Genta F, Yu H, Richiardi G, Fracchioli S, Durando A, Arisio R, Diamandis EP.

Clin Cancer Res. 2000 Aug;6(8):3260-70.

9.

p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.

Saw RP, Morgan M, Koorey D, Painter D, Findlay M, Stevens G, Clarke S, Chapuis P, Solomon MJ.

Dis Colon Rectum. 2003 Feb;46(2):192-202.

PMID:
12576893
10.

P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.

Gadducci A, Di Cristofano C, Zavaglia M, Giusti L, Menicagli M, Cosio S, Naccarato AG, Genazzani AR, Bevilacqua G, Cavazzana AO.

Anticancer Res. 2006 Jan-Feb;26(1B):687-93.

11.

p53 mutation is infrequent in clear cell carcinoma of the ovary.

Ho ES, Lai CR, Hsieh YT, Chen JT, Lin AJ, Hung MH, Liu FS.

Gynecol Oncol. 2001 Feb;80(2):189-93.

PMID:
11161858
12.

Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.

Alvarez AA, Axelrod JR, Whitaker RS, Isner PD, Bentley RC, Dodge RK, Rodriguez GC.

Gynecol Oncol. 2001 Aug;82(2):273-8.

PMID:
11531279
13.

Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Havrilesky L, Darcy kM, Hamdan H, Priore RL, Leon J, Bell J, Berchuck A; Gynecologic Oncology Group Study..

J Clin Oncol. 2003 Oct 15;21(20):3814-25.

PMID:
14551300
14.

[The predictive factors for the response to platinum/paclitaxel based first-line adjuvant chemotherapy in advanced ovarian cancer].

Wei FH, Zhao XD, Zhang Y, He SR, Yang L.

Zhonghua Yi Xue Za Zhi. 2007 May 8;87(17):1187-9. Chinese.

PMID:
17686239
15.

The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer.

Gajra A, Tatum AH, Newman N, Gamble GP, Lichtenstein S, Rooney MT, Graziano SL.

Lung Cancer. 2002 May;36(2):159-65.

PMID:
11955650
16.

Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival.

Pieretti M, Hopenhayn-Rich C, Khattar NH, Cao Y, Huang B, Tucker TC.

Cancer Invest. 2002;20(1):11-23.

PMID:
11852993
17.

TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer.

Santos AM, Sousa H, Portela C, Pereira D, Pinto D, Catarino R, Rodrigues C, Araújo AP, Lopes C, Medeiros R.

Biochem Biophys Res Commun. 2006 Feb 3;340(1):256-62. Epub 2005 Dec 9.

PMID:
16364249
18.

Functional p53 status as a biomarker for chemotherapy response in oral-cavity cancer.

Mroz EA, Rocco JW.

J Clin Oncol. 2010 Feb 10;28(5):715-7. doi: 10.1200/JCO.2009.26.3475. Epub 2010 Jan 4. No abstract available.

PMID:
20048171
19.

TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.

Perrone F, Bossi P, Cortelazzi B, Locati L, Quattrone P, Pierotti MA, Pilotti S, Licitra L.

J Clin Oncol. 2010 Feb 10;28(5):761-6. doi: 10.1200/JCO.2009.22.4170. Epub 2010 Jan 4.

PMID:
20048189
20.

Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses.

Zhang C, Li XP, Cui H, Shen DH, Wei LH.

J Zhejiang Univ Sci B. 2008 Jun;9(6):435-40. doi: 10.1631/jzus.B0820051.

Supplemental Content

Support Center